在第三期随机化安慰剂控制临床试验中,甲福明可以降低SARS-CoV-2
Carolyn T Bramante1, Kenneth B Beckman2, Tanvi Mehta3
1General Internal Medicine, University of Minnesota, Minneapolis, MN.
medRxiv : the preprint server for health sciences
|June 19, 2023
概括
糖尿病药物梅特福林在COVID-19患者中显著降低了SARS-CoV-2病毒载量. 这种安全且廉价的口服药物为减少病毒感染提供了一个有前途的新治疗方案.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 现有的SARS-CoV-2治疗方法面临全球准入,药物相互作用和向特异性的限制.
- 生物物理建模确定了蛋白质翻译作为抗病毒疗法的关键目标.
- 作为一种常见的糖尿病药物,甲胺被确定为一种潜在的蛋白转化抑制剂,向宿主mTor通路.
研究的目的:
- 分析甲胺对COVID-19的门诊患者的SARS-CoV-2病毒载荷的影响.
- 评估甲福明作为抗病毒药物对抗SARS-CoV-2的重用潜力.
主要方法:
- 来自COVID-OUT第3期随机化,安慰剂控制试验的样本的病毒载荷分析.
- 用甲福明治疗的患者与安慰剂治疗的SARS-CoV-2病毒载荷的比较.
- 在并行分析中评估ivermectin和fluvoxamine的病毒学影响.
主要成果:
- 与安慰剂 (p=0.027) 相比,甲福明显示平均SARS-CoV-2病毒载量减少了3.6倍.
- 对于ivermectin或fluvoxamine,没有观察到显著的病毒学影响.
- 甲福明的抗病毒效应在各个患者亚组中一致.
结论:
- 甲胺有效降低SARS-CoV-2病毒载量,支持其作为抗病毒重新定位策略的潜力.
- 这些发现与生物物理模型关于蛋白质翻译作为抗病毒点的预测一致.
- 甲胺是一种安全,易于获得,耐受性良好和廉价的口服选择,用于控制SARS-CoV-2感染.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Oral Hypoglycemic Agents: Sulfonylureas
249
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
249


